Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 2, 2016, Pages 405-412

  Marachelian, Araz ^a   Desai, Ami ^b   Balis, Frank ^b   Katzenstein, Howard ^c   Qayed, Muna ^d   Armstrong, Michael ^e   Neville, Kathleen A ^f   Cohn, Susan L ^g   Bush, Mark ^h   Gunawan, Rudy ⁱ   Lim, Allison Pecha ^j   Smith, Malcolm A ^k   Mary Smith, L ^j  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h WINGATE UNIVERSITY   (United States)

ⁱ ISIS PHARMACEUTICALS   (United States)

^j UNITED THERAPEUTICS CORPORATION   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

ch14.18; Dinutuximab; Pharmacokinetics; Safety; Tolerability; Unituxin

Indexed keywords

ALDESLEUKIN; DINUTUXIMAB; ISOTRETINOIN; SARGRAMOSTIM; ANTINEOPLASTIC AGENT; CH14.18 MONOCLONAL ANTIBODY; GANGLIOSIDE; MONOCLONAL ANTIBODY; SIALOGANGLIOSIDES;

ABDOMINAL PAIN; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; COUGHING; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; ELIMINATION RATE CONSTANT; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNOGENICITY; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; OPEN STUDY; PAIN; PERIPHERAL EDEMA; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PRODUCT PARAMETERS; PROTEIN CONTENT; PRURITUS; RASH; SINGLE DRUG DOSE; URTICARIA; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MONITORING; METABOLISM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GANGLIOSIDES; HUMANS; MALE; NEUROBLASTOMA; TREATMENT OUTCOME;

EID: 84958054880     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2955-9     Document Type: Article

References (15)

1. Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Investig 25(1):67-77. doi: 10.1080/07357900601130763
2. Park JR, Eggert A, Caron H (2010) Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 24(1):65-86. doi: 10.1016/j.hoc.2009.11.011
3. Friedman GK, Castleberry RP (2007) Changing trends of research and treatment in infant neuroblastoma. Pediatr Blood Cancer 49(7 Suppl):1060-1065. doi: 10.1002/pbc.21354
4. Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18(10):2740-2753. doi: 10.1158/1078-0432.ccr-11-1939
5. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202-2211. doi: 10.1056/NEJMra0804577
6. Modak S, Cheung NK (2010) Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 36(4):307-317. doi: 10.1016/j.ctrv.2010.02.006
7. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27(2):289-297. doi: 10.1200/jco.2008.16.6785
8. Berois N, Osinaga E (2014) Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies. Front Oncol 4:114. doi: 10.3389/fonc.2014.00114
9. Soman G, Kallarakal AT, Michiel D, Yang X, Saptharish N, Jiang H, Giardina S, Gilly J, Mitra G (2012) Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody. MAbs 4(1):84-100. doi: 10.4161/mabs.4.1.18566
10. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC (2000) Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 18(24):4077-4085
11. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM (2009) Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 27(1):85-91. doi: 10.1200/jco.2006.10.3564
12. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324-1334. doi: 10.1056/NEJMoa0911123
13. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466-1477
14. Desai AV, Fox E, Smith LM, Lim AP, Maris JM, Balis FM (2014) Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol 74(5):1047-1055. doi: 10.1007/s00280-014-2575-9
15. Ozkaynak MF, Gilman AL, Yu AL, London WB, Sondel PM, Smith MA, Seeger R, Reynolds CP, Maris JM, Park JR (2014) A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. J Clin Oncol 32(5s):suppl. abstract 10044